Repurposing the open access malaria box to discover potent inhibitors of Toxoplasma gondii and Entamoeba histolytica

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 10, 2014, Pages 5848-5854

  Boyom, Fabrice F ^a   Fokou, Patrick V T ^a   Tchokouaha, Lauve R Y ^a,b   Spangenberg, Thomas ^c   Mfopa, Alvine N ^a   Kouipou, Ruffin M T ^a   Mbouna, Cedric J ^a   Donfack, Valerie F Donkeng ^a   Zollo, Paul H A ^a,d  

^a UNIVERSITY OF YAOUNDÉ I   (Cameroon)

^b Institute of Medical Research and Medicinal Plant Studies Yaounde   (Cameroon)

^c Medicines for Malaria Venture   (Switzerland)

^d UNIVERSITY OF NGAOUNDERE   (Cameroon)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAMIDE DERIVATIVE; ANTIAMEBIC AGENT; ANTIMALARIAL AGENT; COCCIDIOSTATIC AGENT; METRONIDAZOLE; MMV 006704; MMV 006861; MMV 007363; MMV 007791; MMV 020548; MMV 085203; MMV 666095; MMV 666600; PIPERAZINE DERIVATIVE; PYRIMETHAMINE; SULFADIAZINE; UNCLASSIFIED DRUG; ANTIPROTOZOAL AGENT; PIPERAZINE;

AMEBIASIS; ANTIPROTOZOAL ACTIVITY; ARTICLE; CELL MEDIATED CYTOTOXICITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG SCREENING; DRUG SELECTIVITY; DRUG SENSITIVITY; ENTAMOEBA HISTOLYTICA; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; NONHUMAN; TOXOPLASMA GONDII; TOXOPLASMOSIS; DRUG EFFECTS; TOXOPLASMA;

ANTIPROTOZOAL AGENTS; ENTAMOEBA HISTOLYTICA; PARASITIC SENSITIVITY TESTS; PIPERAZINES; TOXOPLASMA;

EID: 84907260954     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02541-14     Document Type: Article

References (55)

1. Monzote L, Siddiq A. 2011. Drug development to protozoan diseases. Open Med. Chem. J. 5: 1-3. http://dx.doi.org/10.2174/1874104501105010001.
2. Chadwick EA, Cable J, Chinchen A, Francis J, Guy E, Kean EF, Paul SC, Perkins SE, Sherrard-Smith E, Wilkinson C, Forman DW. 2013. Seroprevalence of Toxoplasma gondii in the Eurasian otter (Lutra lutra) in England and Wales. Parasit. Vectors 6: 75. http://dx.doi.org/10.1186/1756 -3305-6-75.
3. Klaren VN, Kijlstra A. 2002. Toxoplasmosis, an overview with emphasis on ocular involvement. Ocul. Immunol. Inflamm. 10: 1-26. http://dx.doi .org/10.1076/ocii.10.1.1.10330.
4. Glasner PD, Silveira C, Kruszon-Moran D, Martins MC, Burnier M, Jr, Silveira S, Camargo ME, Nussenblatt RB, Kaslow RA, Belfort R, Jr. 1992. An unusually high prevalence of ocular toxoplasmosis in southern Brazil. Am. J. Ophthalmol. 114: 136-144.
5. Roberts F, Mets MB, Ferguson DJ, O'Grady R, O'Grady C, Thulliez P, Brezin AP, McLeod R. 2001. Histopathological features of ocular toxoplasmosis in the fetus and infant. Arch. Ophthalmol. 119: 1-58.
6. Shin DW, Cha DY, Hua QJ, Cha GH, Lee YH. 2009. Seroprevalence of Toxoplasma gondii infection and characteristics of seropositive patients in general hospitals in Daejeon, Korea. Korean J. Parasitol. 47: 125-130. http://dx.doi.org/10.3347/kjp.2009.47.2.125.
7. Silveira C, Belfort R, Jr, Burnier M, Jr, Nussenblatt R. 1988. Acquired toxoplasmic infection as the cause of toxoplasmic retinochoroiditis in families. Am. J. Ophthalmol. 106: 362-364. http://dx.doi.org/10.1016 /0002-9394(88)90382-0.
8. Jones JL, Holland GN. 2010. Annual burden of ocular toxoplasmosis in the United States. Am. J. Trop. Med. Hyg. 82: 464-465. http://dx.doi.org /10.4269/ajtmh.2010.09-0664.
9. Scallan E, Hoekstra RM, Angulo FJ, Tauxe RV, Widdowson MA, Roy SL, Jones JL, Griffin PM. 2011. Foodborne illness acquired in the United States-major pathogens. Emerg. Infect. Dis. 17: 7-15.
10. Dannemann B, McCutchan JA, Israelski D, Antoniskis D, Leport C, Luft B, Nussbaum J, Clumeck N, Morlat P, Chiu J, Vilde JL, Orellana M, Feigal D, Bartok A, Heseltine P, Leedom J, Remington J. 1992. Treatment of toxoplasmic encephalitis in patients with AIDS: a randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. Ann. Intern. Med. 116: 33-43. http://dx.doi.org/10.7326 /0003-4819-116-1-33.
11. Aspinall TV, Joynson DH, Guy E, Hyde JE, Sims PF. 2002. The molecular basis of sulfonamide resistance in Toxoplasma gondii and implications for the clinical management of toxoplasmosis. J. Infect. Dis. 185: 1637-1643. http://dx.doi.org/10.1086/340577.
12. Baatz H, Mirshahi A, Puchta J, Gumbel H, Hattenbach LO. 2006. Reactivation of Toxoplasma retinochoroiditis under atovaquone therapy in an immunocompetent patient. Ocul. Immunol. Inflamm. 14: 185-187. http://dx.doi.org/10.1080/09273940600659740.
13. Ximénez C, Morän P, Rojas L, Valadez A, Gómez A. 2009. Reassessment of the epidemiology of amebiasis: state of the art. Infect. Genet. Evol. 9: 1023-1032. http://dx.doi.org/10.1016/j.meegid.2009.06.008.
14. Bansal D, Malla N, MahajanIndian RC. 2006. Drug resistance in amoebiasis. Indian J. Med. Res. 123: 115-118.
15. Fotedar R, Stark D, Beebe N, Marriott D, Ellis J, Harkness J. 2007. Laboratory diagnostic techniques for Entamoeba species. Clin. Microbiol. Rev. 20: 511-532. http://dx.doi.org/10.1128/CMR.00004-07.
16. Stanley SL, Jr. 2003. Amoebiasis. Lancet 361: 1025-1034. http://dx.doi .org/10.1016/S0140-6736(03)12830-9.
17. Ravdin JI, Stauffer WM. 2005. Entamoeba histolytica (amoebiasis), p 3097-3111. In Mandell GL, Bennett JE, Dolin R (ed), Principles and practice of infectious diseases, vol 2. Churchill Livingstone, Philadelphia, PA.
18. WHO. 1997. WHO/PAHO/UNESCO report: a consultation with experts on amoebiasis. Mexico City, Mexico 28-29 January 1997. Epidemiol. Bull. 18: 13-14.
19. Moran P, Ramos F, Ramiro M, Curiel O, Gonzälez E, Valadez A, Gómez A, Garcïa G, Melendro EI, Ximénez C. 2005. Entamoeba histolytica and/or Entamoeba dispar: infection frequency in HIV/AIDS patients in Mexico City. Exp. Parasitol. 110: 331-334. http://dx.doi.org/10 .1016/j.exppara.2005.03.023.
20. Hung CC, Ji DD, Sun HY, Lee YT, Hsu SY, Ya TL, Shui YH, Sui YC, Cheng HW, Yun HC, Chin FH, Wen CL, Robert C. 2008. Increased risk for Entamoeba histolytica infection and invasive amoebiasis in HIV seropositive men who have sex with men in Taiwan. PLoS Negl. Trop. Dis. 2: e175. http://dx.doi.org/10.1371/journal.pntd.0000175.
21. Samie A, Barrett LJ, Bessong PO, Ramalivhana JN, Mavhandu LG, Njayou M, Gurreant RL. 2010. Seroprevalence of Entamoeba histolytica in the context of HIV and AIDS: the case of the Vhembe district, in South Africa's Limpopo province. Ann. Trop. Med. Parasitol. 104: 55-63. http://dx.doi.org/10.1179/136485910X12607012373911.
22. Watanabe K, Gatanaga H, Escueta-de Cadiz A, Tanuma J, Nozaki T, Oka S. 2011. Amebiasis in HIV-1-infected Japanese men: clinical features and response to therapy. PLoS Negl. Trop. Dis. 5: e1318. http://dx.doi.org /10.1371/journal.pntd.0001318.
23. Chacïn-Bonilla L. 2012. Current pharmacotherapy of amebiasis, advances in new drugs, and design of a vaccine. Invest. Clin. 53: 301-314. (In Spanish.)
24. Spangenberg T, Burrows JN, Kowalczyk P, McDonald S, Wells TNC, Willis P. 2013. The open access Malaria Box: a drug discovery catalyst for neglected diseases. PLoS One 8: e62906. http://dx.doi.org/10.1371/journal .pone.0062906.
25. Pink R, Hudson A, Mouriès MA, Bendig M. 2005. Opportunities and challenges in antiparasitic drug discovery. Nat. Rev. Drug Discov. 4: 727-740. http://dx.doi.org/10.1038/nrd1824.
26. Rosenthal PJ. 2003. Antimalarial drug discovery: old and new approaches. J. Exp. Biol. 206: 3735-3744. http://dx.doi.org/10.1242/jeb.00589.
27. Witty M. 1999. Current strategies in the search for novel antiparasitic agents. Int. J. Parasitol. 29: 95-103. http://dx.doi.org/10.1016/S0020-7519 (98)00193-3.
28. Omura S, Crump A. 2004. The life and times of ivermectin-a success story. Nat. Rev. Microbiol. 2: 984-989. http://dx.doi.org/10.1038 /nrmicro1048.
29. Ridley RG. 2004. Research on infectious diseases requires better coordination. Nat. Med. 10: S137-S140. http://dx.doi.org/10.1038/nm1153.
30. Horton J. 2003. Drug development for tropical diseases-present situation, future perspectives. Trends Parasitol. 19: P06.
31. Sabin AB. 1941. Toxoplasmic encephalitis in children. JAMA 116: 801-807.
32. Mattern CF, Keister DB. 1977. Experimental amebiasis. II. Hepatic amebiasis in the newborn hamster. Am. J. Trop. Med. Hyg. 26: 402-411.
33. Jin C, Kaewintajuk K, Jiang J, Jeong W, Kamata M, Kim HS, Wataya Y, Park H. 2009. Toxoplasma gondii: a simple high-throughput assay for drug screening in vitro. Exp. Parasitol. 121: 132-136. http://dx.doi.org/10 .1016/j.exppara.2008.10.006.
34. Upcroft JA, Upcroft P. 2001. Drug susceptibility testing of anaerobic protozoa. Antimicrob. Agents Chemother. 45: 1810-1814. http://dx.doi .org/10.1128/AAC.45.6.1810-1814.2001.
35. Doggett JS, Nilsen A, Forquer I, Wegmann KW, Jones-Brando L, Yolken RH, Bordón C, Charman SA, Katneni K, Schultz T, Burrows JN, Hinrichs DJ, Meunier B, Carruthers VB, Riscoe MK. 2012. Endochinlike quinolones are highly efficacious against acute and latent experimental toxoplasmosis. Proc. Natl. Acad. Sci. U. S. A. 109: 15936-15941. http://dx.doi.org/10.1073/pnas.1208069109.
36. Djurković-Djaković O, Milenković V, Nikolić A, Bobić B, Grujić J. 2002. Efficacy of atovaquone combined with clindamycin against murine infection with a cystogenic (Me49) strain of Toxoplasma gondii. J. Antimicrob. Chemother. 50: 981-987. http://dx.doi.org/10.1093/jac/dkf251.
37. Tipparaju SK, Muench SP, Mui EJ, Ruzheinikov SN, Lu JZ, Hutson SL, Kirisits MJ, Prigge ST, Roberts CW, Henriquez FL, Kozikowski AP, Rice DW, McLeod RL. 2010. Identification and development of novel inhibitors of Toxoplasma gondii enoyl reductase. J. Med. Chem. 53: 6287-6300. http://dx.doi.org/10.1021/jm9017724.
38. Sun A, Prussia A, Zhan W, Murray EE, Doyle J, Cheng LT, Yoon JJ, Radchenko EV, Palyulin VA, Compans RW, Liotta DC, Plemper RK, Snyder JP. 2006. Nonpeptide inhibitors of measles virus entry. J. Med. Chem. 49: 5080-5092. http://dx.doi.org/10.1021/jm0602559.
39. Hedstrom LK, Striepen B. June 2007. IMP dehydrogenase inhibitors for treating mammalian gastrointestinal parasitic infections. Patent WO2007143557.
40. Ang W, Lin YN, Tao Y, Yang JZ, Pi WY, Yang YH, Luo YF, Deng Y, Wei YQ. 2012. Synthesis and biological evaluation of 2-(3-fluoro-4-nitro phenoxy)- N-phenylacetamide derivatives as novel potential affordable antitubercular agents. Molecules 17: 2248-2258. http://dx.doi.org/10.3390 /molecules17022248.
41. Lee K, Roh SH, Xia Y, Kang KW. 2011. Synthesis and biological evaluation of phenoxy-N-phenylacetamide derivatives as novel P-glycoprotein inhibitors. Bull. Korean Chem. Soc. 32: 3666-3674. http://dx.doi.org/10 .5012/bkcs.2011.32.10.3666.
42. Bessoff K, Spangenberg T, Foderaro JE, Jumani RS, Ward GE, Huston CD. 2014. Identification of Cryptosporidium parvum active chemical series by repurposing the open access Malaria Box. Antimicrob. Agents Chemother. 58: 2731-2739. http://dx.doi.org/10.1128/AAC.02641-13.
43. Sobrin L, Kump LI, Foster CS. 2007. Intravitreal clindamycin for toxoplasmic retinochoroiditis. Retina 27: 952-957. http://dx.doi.org/10.1097 /IAE.0b013e31804b3f0d.
44. Soheilian M, Ramezani A, Azimzadeh A, Sadoughi MM, Dehghan MH, Shahghadami R, Yaseri M, Peyman GA. 2011. Randomized trial of intravitreal clindamycin and dexamethasone versus pyrimethamine, sulfadiazine, and prednisolone in treatment of ocular toxoplasmosis. Ophthalmology 118: 134-141. http://dx.doi.org/10.1016/j.ophtha.2010.04.020.
45. Soheilian M, Sadoughi MM, Ghajarnia M, Dehghan MH, Yazdani S, Behboudi H, Anisian A, Peyman GA. 2005. Prospective randomized trial of trimethoprim/sulfamethoxazole versus pyrimethamine and sulfadiazine in the treatment of ocular toxoplasmosis. Ophthalmology 112: 1876-1882. http://dx.doi.org/10.1016/j.ophtha.2005.05.025.
46. Bowman JD, Merino EF, Brooks CF, Striepen B, Carlier PR, Cassera MB. 2014. Anti-apicoplast and gametocytocidal screening to identify the mechanisms of action of compounds within the Malaria Box. Antimicrob. Agents Chemother. 58: 811-819. http://dx.doi.org/10.1128/AAC.01500-13.
47. Gomes MAGB, Carvalho LP, Rocha BS, Oliveira RR, de Melo EJT, Maria EJ. 2013. Evaluating anti-Toxoplasma gondii activity of new series of phenylsemicarbazone and phenylthiosemicarbazones in vitro. Med. Chem. Res. 22: 3574-3580. http://dx.doi.org/10.1007/s00044-012-0347-9.
48. Derouin F, Santillana-Hayat M. 2000. Anti-Toxoplasma activities of antiretroviral drugs and interactions with pyrimethamine and sulfadiazine in vitro. Antimicrob. Agents Chemother. 44: 2575-2577. http://dx.doi.org /10.1128/AAC.44.9.2575-2577.2000.
49. Payne AJ, Neal LM, Knoll LJ. 2013. Fusidic acid is an effective treatment against Toxoplasma gondii and Listeria monocytogenes in vitro, but not in mice. Parasitol. Res. 112: 3859-3863. http://dx.doi.org/10.1007/s00436 -013-3574-1.
50. Saleh A, Friesen J, Baumeister S, Gross U, Bohne W. 2007. Growth inhibition of Toxoplasma gondii and Plasmodium falciparum by nanomolar concentrations of 1-hydroxy-2-dodecyl-4(1H)quinolone, a highaffinity inhibitor of alternative (type II) NADH dehydrogenases. Antimicrob. Agents Chemother. 51: 1217-1222. http://dx.doi.org/10.1128/AAC .00895-06.
51. Bajohr LL, Ma L, Platte C, Liesenfeld O, Tietze LF, Groß U, Bohne W. 2010. In vitro and in vivo activities of 1-hydroxy-2-alkyl-4(1H)quinolone derivatives against Toxoplasma gondii. Antimicrob. Agents Chemother. 54: 517-521. http://dx.doi.org/10.1128/AAC.01001-09.
52. Kimura M, Nakamura T, Nawa Y. 2007. Experience with intravenous metronidazole to treat moderate-to-severe amebiasis in Japan. Am. J. Trop. Med. Hyg. 77: 381-385.
53. Moon TD, Oberhelman RA. 2005. Antiparasitic therapy in children. Pediatr. Clin. North Am. 52: 917-948. http://dx.doi.org/10.1016/j.pcl.2005.02.012.
54. Buckner FS, Waters NC, Avery VM. 2012. Recent highlights in antiprotozoan drug development and resistance research. Int. J. Parasitol. Drugs Drug Resist. 2: 230-270. http://dx.doi.org/10.1016/j.ijpddr.2012.05 .002.
55. Debnath A, Parsonage D, Andrade RM, He C, Cobo ER, Hirata K, Chen S, Garcïa-Rivera G, Orozco E, Martïnez MB, Gunatilleke SS, Barrios AM, Arkin MR, Poole LB, McKerrow JH, Reed SL. 2012. A high throughput drug screen for Entamoeba histolytica identifies a new lead and target. Nat. Med. 18: 956-960. http://dx.doi.org/10.1038/nm.2758.